Swiss Digital Pharmacy Market: 2025 Outlook and Key Metrics

The Swiss pharmaceutical retail landscape is undergoing a structured digital transformation, driven by evolving consumer expectations and technological advancements. As of 2025, the digital channel represents a growing, albeit regulated, segment within the broader health and wellness market. This analysis presents key statistical data and market projections for Switzerland’s online pharmacy sector.

Market Size and Growth Projections for 2025

The Swiss digital pharmacy market, encompassing online sales of over-the-counter (OTC) products, health supplements, personal care items, and to a limited extent, prescription medications, continues its upward trajectory. While smaller than its German counterpart, the market demonstrates robust growth, reflecting increasing consumer comfort with online health purchases and the expanding digital offerings of established pharmacy groups.

Quantisintel analysis projects the total market value for digital pharmacy retail in Switzerland to reach CHF 680 million by the end of 2025. This figure primarily encompasses sales from online platforms operated by traditional pharmacies, pure-play online pharmacies, and health product e-tailers. The growth is underpinned by a sustained compound annual growth rate (CAGR) observed since 2022.

Note: Rx sales share is subject to strict regulatory conditions and availability of e-prescriptions.

The growth rate of 14.8% CAGR for 2023-2025 positions digital pharmacy as a significant growth driver within Swiss retail e-commerce. This expansion is notably higher than the projected 7.5% CAGR for the overall Swiss retail e-commerce market during the same period, indicating a strong shift in consumer purchasing habits for health-related goods.

Consumer Adoption and Digital Penetration

Consumer adoption of digital channels for pharmacy purchases in Switzerland is steadily advancing, influenced by convenience, product availability, and competitive pricing. Data indicates a growing segment of the Swiss population is utilizing online platforms for their health and wellness needs.

As of Q4 2024, approximately 32% of Swiss adults reported having purchased pharmacy or health-related products online at least once in the preceding 12 months. This represents a 6 percentage point increase from Q4 2022 figures. The frequency of online purchases is also increasing, with 18% of these digital consumers making repeat purchases on a quarterly basis.

Mobile commerce plays a dominant role in this sector. In 2024, 63% of digital pharmacy transactions were initiated and completed via mobile devices, including smartphones and tablets. This mobile-first trend underscores the importance of optimized user interfaces and seamless mobile payment solutions for digital pharmacy providers in Switzerland.

Key product categories driving online sales include:

• Over-the-Counter (OTC) Medication: Pain relievers, cold and flu remedies, digestive aids, and allergy medications constitute the largest segment, accounting for 78% of digital pharmacy revenue.
• Vitamins, Supplements, and Health Foods: This category continues to show robust demand online, contributing approximately 12% of sales.
• Dermocosmetics and Personal Care: High-margin beauty and personal care products sold through pharmacy channels make up about 8% of online sales.
• Prescription (Rx) Medication: While growing, this segment remains small at 5%, primarily due to existing regulatory frameworks and the slower adoption of digital prescription processes (E-Rezept).

The average order value (AOV) for digital pharmacy purchases in Switzerland reached CHF 88.50 in 2024, an increase from CHF 85.00 in 2023. This higher AOV compared to general e-commerce is often attributed to bundled purchases of multiple health products and the inclusion of higher-value specialized items.

Regulatory Framework and E-Prescription Developments

The regulatory landscape significantly shapes the scope and growth of digital pharmacy retail in Switzerland. The Schweizerisches Heilmittelinstitut (Swissmedic) is the national authority responsible for the authorization and supervision of therapeutic products, including those sold online.

Key regulatory aspects impacting digital pharmacy operations include:

• Authorization for Online Sales: Pharmacies operating online must hold a valid operating license from Swissmedic and comply with stringent requirements regarding product sourcing, storage, and dispensing.
• Prescription Medication (Rx) Sales: The online sale of prescription-only medication is permitted under strict conditions. This typically requires a valid prescription issued by a Swiss-licensed physician. The dispensing pharmacy must also be a licensed Swiss pharmacy. Direct-to-consumer online sales of Rx medications without a valid, verifiable prescription are prohibited.
• OTC Medication Sales: Online sales of OTC medications are more widely permitted, provided the selling entity adheres to Swissmedic guidelines for labeling, information provision, and quality assurance.
• Data Protection: Adherence to Swiss data protection laws (e.g., nDSG) and EU GDPR standards (where applicable, for cross-border data flows) is mandatory, especially concerning sensitive health data.

The introduction and gradual adoption of the E-Rezept (e-prescription) system represent a pivotal development for the Rx segment of digital pharmacy. While implementation has been phased and varies by canton and healthcare provider, the E-Rezept aims to streamline the prescription process, reduce errors, and facilitate digital dispensing. As of early 2025, the full nationwide integration of E-Rezept is still in progress, impacting the speed at which Rx sales can fully transition online. Current data indicates that less than 10% of all prescriptions are processed digitally for online fulfillment, a figure projected to rise modestly to 15% by 2025 as infrastructure and user acceptance improve.

Competitive Landscape and Digital Presence

The Swiss digital pharmacy market is characterized by a mix of traditional pharmacy chains expanding their online footprint and specialized online-only providers. The competitive intensity is increasing as established players invest in their digital channels and logistics capabilities.

Leading entities with significant digital presence in Switzerland include:

• Zur Rose Group (including DocMorris Switzerland): A prominent player in the DACH region, Zur Rose Group maintains a strong digital presence in Switzerland, offering a broad range of OTC products, beauty items, and facilitating prescription fulfillment. Their market share in the overall Swiss digital pharmacy segment is estimated at 28% for 2024.
• Coop Vitality: As a joint venture between Coop and Galenica, Coop Vitality operates a substantial network of physical pharmacies alongside a robust e-commerce platform. Their digital channel focuses on OTC, supplements, and personal care, securing an estimated 20% market share in 2024.
• Amavita (Galenica Group): Another key brand under the Galenica Group, Amavita also offers a comprehensive online store complementing its physical locations. Their digital market share is estimated at 15% for 2024.
• Independent Pharmacies and Smaller Chains: A fragmented segment comprising numerous smaller pharmacies and regional chains, many of whom have established their own online shops or participate in collective online platforms. This segment collectively accounts for approximately 30% of the digital pharmacy market.
• International Pure-Play Online Pharmacies: A smaller segment due to regulatory barriers and local market preferences, these players hold an estimated 7% market share.

Investments in user experience, delivery speed, and digital health services (e.g., online consultations, digital health records integration) are key areas of competition. The ability to seamlessly integrate online and offline channels (omnichannel strategy) is proving to be a critical success factor for traditional pharmacy groups.

Frequently Asked Questions

What is the projected market value of Switzerland’s digital pharmacy sector in 2025? Quantisintel analysis projects the total market value for digital pharmacy retail in Switzerland to reach CHF 680 million by the end of 2025. This figure primarily encompasses sales from online platforms operated by traditional pharmacies, pure-play online pharmacies, and health product e-tailers.

What is the growth rate for the Swiss digital pharmacy market from 2023 to 2025? The Swiss digital pharmacy market is projected to grow at a Compound Annual Growth Rate (CAGR) of +14.8% from 2023 to 2025. This expansion is notably higher than the projected 7.5% CAGR for the overall Swiss retail e-commerce market during the same period.

What percentage of Swiss consumers use online channels for pharmacy purchases? As of Q4 2024, approximately 32% of Swiss adults reported having purchased pharmacy or health-related products online at least once in the preceding 12 months. This marks a 6 percentage point increase from Q4 2022 figures.

Which product categories primarily drive online pharmacy sales in Switzerland? Over-the-Counter (OTC) medication constitutes the largest segment, accounting for 78% of digital pharmacy revenue. Vitamins, supplements, and health foods contribute approximately 12% of sales, followed by dermocosmetics and personal care at about 8%.

What is the market share of leading digital pharmacy providers in Switzerland? For 2024, Zur Rose Group holds an estimated 28% market share in the overall Swiss digital pharmacy segment. Coop Vitality secures an estimated 20% market share, while Amavita (Galenica Group) holds approximately 15%.

For deeper strategic analysis, see our full report.

The Swiss digital pharmacy market is on track to reach a projected value of CHF 680 million by the end of 2025, driven by a robust 14.8% CAGR from 2023. This expansion reflects increasing consumer adoption, with 32% of Swiss adults having purchased pharmacy or health-related products online in Q4 2024.